GUBRA (GUBRA) News
Follow GUBRA (GUBRA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Gubra Narrows 2026 CRO Revenue Growth Guidance to 2–6%
Gubra narrowed its 2026 guidance for CRO revenue growth to 2–6%.
EARNINGS | Nov 06, 2026, 06:06 AM UTC
M
Gubra targets average annual organic revenue growth of 10% toward 2030
EQUITY | Oct 27, 2026, 07:07 AM UTC
L
Gubra A/S (GUBRA) Partner Shows Phase 1 ABBV-295 Tolerability, PK
Gubra said partner AbbVie presented detailed Phase 1 data for ABBV-295, a long-acting amylin analog, showing favorable tolerability and pharmacokinetics supporting dosing beyond weekly in a 12/13-week MAD study.Material
NEWS | Sep 30, 2026, 09:50 AM UTC
M
Gubra partner Hemab Therapeutics doses first volunteer in HMB-003 Phase 1
Gubra said Hemab Therapeutics dosed the first healthy volunteer in a randomized, placebo-controlled Phase 1 trial of HMB-003, a peptide-based plasmin inhibitor for heavy menstrual bleeding.
EQUITY | Sep 17, 2026, 12:45 PM UTC
L
Gubra to participate in Morgan Stanley Global Healthcare Conference
Gubra will take part in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14-16. CEO Markus Rohrwild joins a fireside chat on September 16 at 1:50 p.m. EDT.
EQUITY | Sep 09, 2026, 01:00 PM UTC